Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)

PHASE3CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

January 10, 2005

Primary Completion Date

January 24, 2008

Study Completion Date

January 24, 2008

Conditions
Short Bowel Syndrome
Interventions
DRUG

teduglutide 0.05 mg/kg/d

0.05 mg/kg/d subcutaneous injection

DRUG

teduglutide 0.10 mg/kg/d

0.10 mg/kg/d subcutaneous injection

Trial Locations (21)

1070

Hôpital Erasme, Brussels

2100

Rigshospitalet, Copenhagen

12208

Albany Medical Center, Albany

14642

University of Rochester Medical Center, Rochester

15213

University of Pittsburgh Medical Center, Pittsburgh

19104

University of Pennsylvania - Penn Nursing, Philadelphia

30322

Emory University Hospital, Atlanta

44195

The Cleveland Clinic Foundation, Cleveland

59037

Hôpital Huriez, Lille

68198

University of Nebraska Medical Center, Omaha

69317

Hôpital de la Croix-Rousse, Lyon

85259

Mayo Clinic Scottsdale, Scottsdale

92110

Hôpital Lariboisière, Paris

02903

Rhode Island Hospital, Providence

V6Z1Y6

St. Paul's Hospital, Vancouver

M5B1W8

St. Michael's Hospital, Toronto

M5G2N2

Toronto General Hospital, Toronto

1100 DD

Academic Medical Center, Department of Endocrinology & Metabolism, Amsterdam

10-561

Pracownia Żywienia, Olsztyn

00-416

Samodzielny Publiczny Szpital Kliniczny-Im.prof W.Orłowskiego CMKP, Warsaw

HAI3UJ

St. Mark's Hospital, Harrow

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Shire

INDUSTRY